Updated

(Reuters) – Sage Therapeutics Inc said on Monday its oral treatment for postpartum depression met the main goal of reducing symptoms of the condition, when compared to a placebo in a late-stage study, sending its shares up...

By Lisa Rapaport (Reuters Health) – Hospital efforts to support breastfeeding by having babies “room-in” with mothers may have a rare unintended consequence: an increased risk of newborn falls. Neonatal falls...

By Peter Szekely NEW YORK (Reuters) – A former patient at a New Jersey surgical facility that state health officials said may have exposed thousands of patients to HIV and other blood-borne pathogens has tested positive...

(Reuters) – A U.S. unit of Indian generic drugmaker Aurobindo Pharma Ltd will recall 80 lots of medicines containing blood pressure drug valsartan that were found to have a probable cancer-causing impurity, according to...

(Reuters) – Capricor Therapeutics Inc said on Wednesday it had put on hold a clinical trial of its drug to treat Duchenne muscular dystrophy (DMD), a muscle-wasting disorder, citing a safety review. The review follows a...

BEIJING (Reuters) – China has detected the African swine fever virus in some protein powders made using pork blood and manufactured by a Tianjin-based company, the General Administration of Customs said in a statement on...

(Reuters) – Merck KGaA and Pfizer Inc said on Friday they were ending a late-stage study for their drug to treat a form of ovarian cancer in previously untreated patients. The results showed the drug, Bavencio, in...

(Reuters) – The U.S. Food and Drug Administration on Friday approved Stemline Therapeutics Inc’s Elzonris for the treatment of a rare blood disease in adults and children aged two years and above. This is the first...

By Manas Mishra (Reuters) – The U.S. Food and Drug Administration approved on Friday Alexion Pharmaceuticals Inc’s rare blood disorder drug Ultomiris, an early backing that also solidifies the company’s...

By Caroline Humer and John Miller NEW YORK/ZURICH (Reuters) – Biogen Inc’s Spinraza treatment for spinal muscular atrophy and Swiss drugmaker Novartis AG’s experimental gene therapy are both expensive, but the...